Credits: Canva
Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.
The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.
The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.
The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.
The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.
The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.
Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."
The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.
However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Retatrutide has not yet received FDA approval. (Photo credit: AI generated)
Retatrutide, Eli Lilly’s new weight-loss drug, is in the final stages of its clinical trial, and the results seem very promising, the drugmaker said on Thursday. In a news release, they disclosed that the brand-new drug helped people lose up to 30 per cent of their body weight, which is about 85 pounds. The results are on a par with bariatric surgery, which helps people shed approximately 25 to 35 per cent of their total body weight within one to two years. Doctors say that this is the largest weight loss ever witnessed in a medical trial. While Lilly has not yet filed for approval from the Food and Drug Administration, the pharma giant says that it expects to file this year.
Retatrutide is similar to drugs like Zepbound and Wegovy that mimic the GLP-1 hormone. Retatrutide, however, along with GLP-1, mimics glucagon as well, thereby working like a triple agonist. This is unlike Zepbound, which is a double agonist. Researchers said that they have witnessed the impact of semaglutide and tirzepatide. However, Retatrutide's results went beyond the current weight-loss drugs on the market.
Dr Shauna Levy, medical director of the Tulane Weight Loss Center, explained that the current GLP-1s are not good enough to induce weight loss in people dealing with severe obesity and those who have a BMI of 35. Bariatric surgery can provide the same, but it seems that Retatrutide will be far more effective for people living with a high BMI who are trying to achieve a healthy weight.
Read more: Meet Retatrutide: The Unapproved Cousin Of Ozempic That Supports Weight Loss Differently
Retatrutide was in the third phase of its trials involving 2,300 obese or overweight participants. While the full results have not yet been released in a medical journal, participants who took the highest dose of the drug lost 28 per cent of their body weight, approximately 70 pounds. Furthermore, nearly half of the participants lost over 30 per cent of their body weight. The trial continued for 80 weeks, and a small group of severely obese patients took the drug for 104 weeks and lost about 85 pounds on average. Alternatively, patients who took high doses of Zepbound lost around 21 per cent of their body weight in 72 weeks. Wegovy users lost about 15 per cent of their weight in 68 weeks.
On the downside, there were some side effects too. Retatrutide users experienced the following side effects:
These have, however, been seen with GLP-1 drugs.
Retatrutide might be the next big weight-loss drug set to hit the market soon. It aims to maximise weight-loss results with fewer side effects for users. If approved, it could be helpful for patients who are struggling to lose weight on the current versions of GLP-1 drugs.
Credit: iStock
A 24-year-old student from West Bengal has reportedly become the first confirmed heatstroke case of the season in India’s national capital.
According to doctors at Dr Ram Manohar Lohia (RML) Hospital, the young man was admitted in critical condition after developing hyperpyrexia — an extremely high body temperature, and altered mental status while travelling by train to the national capital.
"We received our first heatstroke patient at the RML Hospital on the intervening night of May 20-21. The 24-year-old youth from West Bengal was travelling on a train when his health deteriorated,” said Dr Ajay Chauhan, Director Professor of Medicine, at RML, PTI reported.
“He was brought to the hospital in an unconscious state. We took immediate action and tried to cool down his body,” he said, adding that the boy "is admitted to the medicine ward and is still critical".
As per the doctors, the student had no known pre-existing medical condition, and other possible causes of his symptoms were ruled out before heatstroke was diagnosed.
Heatstroke is the most severe form of heat-related illness and is considered a medical emergency. It occurs when the body loses its ability to regulate temperature due to prolonged exposure to extreme heat or dehydration. In most cases, body temperature rises above 104°F (40°C), which can damage the brain, heart, kidneys, and muscles.
“The general features of a patient with heat stroke are: first, his or her body temperature will be very high. It will not be around normal levels like 104, 105, or 106—it will be significantly elevated. Second, the person may be delirious, confused, or even in a state of unconsciousness or coma. The breathing will also be labored,” Dr. Naval Vikram, Professor, Department of Medicine, at the AII India Institute of Medical Sciences (AIIMS), told HealthandMe.
During a heatwave, most patients improve quickly with rest, oral fluids, cooling measures, and moving to a shaded or air-conditioned environment.
"However, if heat exposure continues and the body’s cooling mechanisms begin to fail, the condition can progress to heat stroke, which is a medical emergency. In heat stroke, body temperature often rises above 104°F," Dr. Vaibhav Mishra, Senior Director & Head, CTVS, Max Super Speciality Hospital, told HealthandMe.
What may initially appear as confusion, disorientation, or irrelevant talking can rapidly worsen into:
Also read: Bundibugyo Ebola Cases Rise To 600 As Scientists Investigate Spillover Event
While it may be impossible to avoid rising temperatures, the focus should be on how much you can protect yourself. Experts suggest the following measures:
The India Meteorological Department (IMD) has warned of severe temperatures across several states.
"Heat wave to severe heat wave conditions likely to continue to prevail over northwest & central India during the week and over East India during the next 5 days," the IMD said, in its latest update on May 20.
It added that severe heat conditions will persist for at least the next 72 hours across Delhi-NCR, Rajasthan, Uttar Pradesh, Punjab, and Haryana. Temperatures in several cities are expected to touch 47°C to 48°C, with Banda currently emerging as the hottest place in the country.
Alzheimer's disease is usually diagnosed after 60 years. (Photo credit: AI generated)
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide, and it has a long preclinical stage. It is mostly diagnosed at an advanced age, but according to doctors, it begins years before the symptoms become evident. New research shows that blood biomarkers, along with self-reported memory concerns, could give an explanation as to how Alzheimer's disease worsens over time. Therefore, the best time to nourish brain health is during your 40s or 50s.
For this study, researchers used data from the Dunedin Study at the University of Otago, which had been following a few participants for over 50 years. Researchers found a protein known as pTau181, which is associated with self-reported problems linked to memory and thinking skills. Participants were 45 years old at the time of assessment. Typically, an Alzheimer's diagnosis happens at or after the age of 65–70.
When it comes to Alzheimer's, the treatments could only slow down disease progression, but they do not fully restore cognitive function, which is usually lost in the advanced stages. Researchers noted that these treatments work best when taken early, which makes it important to identify the early signs of Alzheimer's disease.
Researchers noted that different types of dementia can look different at various stages of the disease. However, the course of progression and treatment can vary from patient to patient. In the past, Alzheimer's could only be diagnosed post-mortem or through invasive procedures such as lumbar punctures. However, researchers are now working towards identifying blood biomarkers that could offer minimally invasive ways to identify high-risk patients for Alzheimer's.
Researchers note that Alzheimer's can be detected in the early stages, and this could provide an opportunity for prevention. It may also offer health benefits for ageing and the brain. Some lifestyle changes include supporting people to remain active, continue engaging in social activities, and address factors such as hearing loss or hypertension. Preventive approaches in this case have worked more effectively the sooner they are implemented. Therefore, it is important to study middle-aged populations, as the signs can start appearing long before the disease is finally diagnosed.
As people get older, they notice that their memory is not as strong as it used to be. Forgetfulness gradually becomes a common issue with advancing age. However, in some cases, these problems indicate a different story altogether. Recent research shows that minor changes in cognition often begin long before diagnosis, and that is the first moment the disease is truly felt.
When it comes to screening for biological markers, combining them with subjective memory function reports can help distinguish the earliest signs of Alzheimer's from normal ageing. Proteins such as pTau181 are much higher in Alzheimer's patients, but researchers have not yet ascertained when they begin to accumulate. While researchers did not find that pTau181 was linked to MRI scans measuring cognitive test performance at 45, there were two possible explanations for this:
© 2024 Bennett, Coleman & Company Limited